United Therapeutics Corp.

UTHR

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001082554

A

strongest fifth of 370 graded peers in healthcare

rank 26 of 370; percentile 6.8; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard

Profitability	C	percentile 48.0
Solvency	A	percentile 12.0
Growth and financing	B	percentile 33.6
Reliability	0.94 AUC	filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets	total assets $7.9B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: fortress balance sheet
Inputs computable	11 of 14	
Graded from	filings received through Feb 25, 2026	257 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$562.28	2026-11-06; market equity $23.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension (PAH), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies. As a public benefit corporation (PBC), we aim to deliver meaningful impacts for our patients, our people, our shareholders, and other stakeholders.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 48.0						
Gross profitability	35.5%	32.3%		38.5	365	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(3.0%)	(6.6%)	71.5	802	2025-12-31
Gross margin stability, five years	1.9 pts	2.8 pts	34.0	242	2025-12-31
Solvency, sleeve percentile 12.0					
Twelve-month failure probability	0.02%	0.08%	4.8	249	2026-09-30
Altman Z double-prime	16.93	(0.37)	3.5	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	6.60x	2.94x	27.8	828	2025-12-31
Growth and financing, sleeve percentile 33.6					
Revenue growth, three-year compound	18.0%	10.0%	34.8	412	2025-12-31
Free cash flow growth, three-year compound	16.2%	10.9%	46.3	96	2025-12-31
Reinvestment rate	37.9%	37.1%	48.1	105	2025-12-31
Asset growth, three years	9.2%	2.2%	32.7	696	2025-12-31
Net share issuance, one year	(2.4%)	2.5%	6.4	630	2026-02-18

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
21	SBC Medical Group Holdings Inc. (SBCWW)	5.3	A	fortress balance sheet
22	Neurocrine Biosciences Inc. (NBIX)	5.7	A	
23	Crispr Therapeutics AG (CRSP)	6.0	A	
24	Ideaya Biosciences, Inc. (IDYA)	6.2	A	
25	AtriCure, Inc. (ATRC)	6.5	A	
26	United Therapeutics Corp. (UTHR)	6.8	A	
27	Gyre Therapeutics, Inc. (GYRE)	7.0	A	fortress balance sheet
28	Hims & Hers Health, Inc. (HIMS)	7.3	A	
29	Viridian Therapeutics, Inc.\DE (VRDN)	7.6	A	dilution, fortress balance sheet
30	iRhythm Holdings, Inc. (IRTC)	7.9	A	fortress balance sheet
31	Veracyte, Inc. (VCYT)	8.1	A	

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	21.7%	(2.1%)	63
Distance from 52-week high	(7.6%)	(30.4%)	80
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	4.3%	(1.0%)	79
Book value to price	0.26	0.29	47
Sales to price	0.13	0.30	32
Composite equity issuance, five years	(4.5%)	20.8%	21

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	0.03	(0.19)	63

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.2B
Operating cash flow, four quarters	$1.4B
Months of runway	not finite
Days since last periodic filing	5 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$285.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$2.8B	2025-12-31	2026-02-25	10-K	26-000006
2	assets	us-gaap:Assets	$7.9B	2025-12-31	2026-02-25	10-K	26-000006
3	net income	us-gaap:NetIncomeLoss	$1.3B	2025-12-31	2026-02-25	10-K	26-000006
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.6B	2025-12-31	2026-02-25	10-K	26-000006
5	assets	us-gaap:Assets	$7.4B	2024-12-31	2026-02-25	10-K	26-000006
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.2B	2025-12-31	2026-02-25	10-K	26-000006
7	gross profit	us-gaap:GrossProfit	$2.6B	2024-12-31	2026-02-25	10-K	26-000006
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.9B	2024-12-31	2026-02-25	10-K	26-000006
9	gross profit	us-gaap:GrossProfit	$2.1B	2023-12-31	2026-02-25	10-K	26-000006
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.3B	2023-12-31	2026-02-25	10-K	26-000006
11	gross profit	us-gaap:GrossProfit	$1.8B	2022-12-31	2025-02-26	10-K	25-000005
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.9B	2022-12-31	2025-02-26	10-K	25-000005
13	gross profit	us-gaap:GrossProfit	$1.6B	2021-12-31	2024-02-21	10-K	24-000005
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.7B	2021-12-31	2024-02-21	10-K	24-000005
15	current assets	us-gaap:AssetsCurrent	$3.7B	2025-12-31	2026-02-25	10-K	26-000006
16	current liabilities	us-gaap:LiabilitiesCurrent	$560.6M	2025-12-31	2026-02-25	10-K	26-000006
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$8.6B	2025-12-31	2026-02-25	10-K	26-000006
18	operating income	us-gaap:OperatingIncomeLoss	$1.5B	2025-12-31	2026-02-25	10-K	26-000006
19	book equity	us-gaap:StockholdersEquity	$7.1B	2025-12-31	2026-02-25	10-K	26-000006
20	liabilities	us-gaap:Liabilities	$783.8M	2025-12-31	2026-02-25	10-K	26-000006
21	operating income	us-gaap:OperatingIncomeLoss	$1.2B	2023-12-31	2026-02-25	10-K	26-000006
22	interest expense	us-gaap:InterestExpense	$59.3M	2023-12-31	2024-02-21	10-K	24-000005
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$520.5M	2025-12-31	2026-02-25	10-K	26-000006
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.3B	2024-12-31	2026-02-25	10-K	26-000006
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$246.5M	2024-12-31	2026-02-25	10-K	26-000006
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$978.0M	2023-12-31	2026-02-25	10-K	26-000006
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$230.4M	2023-12-31	2026-02-25	10-K	26-000006
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$802.5M	2022-12-31	2025-02-26	10-K	25-000005
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$138.8M	2022-12-31	2025-02-26	10-K	25-000005
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$85.6M	2025-12-31	2026-02-25	10-K	26-000006

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.7B	2025-12-31	2026-02-25	10-K	26-000006
32	income tax	us-gaap:IncomeTaxExpenseBenefit	$379.2M	2025-12-31	2026-02-25	10-K	26-000006
33	current assets	us-gaap:AssetsCurrent	$3.9B	2024-12-31	2026-02-25	10-K	26-000006
34	current liabilities	us-gaap:LiabilitiesCurrent	$738.1M	2024-12-31	2026-02-25	10-K	26-000006
35	assets	us-gaap:Assets	$7.2B	2023-12-31	2025-02-26	10-K	25-000005
36	assets	us-gaap:Assets	$6.0B	2022-12-31	2024-02-21	10-K	24-000005
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	43,827,686	2026-02-18	2026-02-25	10-K	26-000006
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	44,912,177	2025-02-19	2025-02-26	10-K	25-000005

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.